Bristol Myers Squibb's Sotyktu Gains EU Nod for Treatment of Active Psoriatic Arthritis
MT Newswires Live05-08
Bristol Myers Squibb (BMY) said Friday that the European Commission approved Sotyktu for adults with active psoriatic arthritis who had an inadequate response or intolerance to prior disease-modifying antirheumatic drug therapy.
Sotyktu is the first and only TYK2 inhibitor approved in the EU for active psoriatic arthritis and can be used alone or with methotrexate, the company said.
The approval was supported by Phase 3 POETYK PsA-1 and PsA-2 trial results showing Sotyktu outperformed placebo at Week 16 across joint and skin symptom measures and quality-of-life endpoints, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
